Short Bowel Syndrome Market - Global Forecast 2026-2032

The Short Bowel Syndrome Market is projected to reach USD 1.32 Billion in 2026. It is expected to continue growing at a CAGR of 9.50%, reaching USD 2.31 Billion by 2032.

Short bowel syndrome (SBS) is a rare, high-burden intestinal failure condition caused by inadequate absorptive capacity after major bowel resection, congenital bowel loss, or severe functional impairment. It is strongly associated with dependence on parenteral nutrition or intravenous fluids, recurrent dehydration, electrolyte imbalance, catheter-related bloodstream infection, kidney complications, and intestinal failure-associated liver disease.

For pharmaceutical and biotechnology stakeholders, the short bowel syndrome market is defined by orphan-disease economics, specialized prescribing, and measurable clinical endpoints such as reduced parenteral support volume, fewer infusion days, improved hydration, and intestinal adaptation. FDA- and EMA-approved teduglutide established GLP-2 analog therapy as a validated pathway for eligible adults and pediatric patients, while next-generation enteroendocrine, microbiome, and regenerative approaches are reshaping long-term SBS treatment strategies.

Transformative Shifts in the SBS Treatment Landscape

The SBS landscape is shifting from lifelong nutritional replacement toward targeted intestinal rehabilitation. Multidisciplinary care models now combine diet optimization, oral rehydration strategies, anti-motility therapy, acid suppression, micronutrient management, home parenteral nutrition, surgical reconstruction, and GLP-2-based pharmacotherapy to reduce dependence on parenteral support.

Innovation is also moving toward longer-acting peptides, pediatric-friendly formulations, real-world evidence generation, and earlier intervention after bowel resection. Commercial success increasingly depends on demonstrating durability, safety in chronic use, reduction in hospital utilization, lower catheter-related complication burden, and compatibility with established intestinal failure programs.

Cumulative Impact of Artificial Intelligence on SBS Innovation

Artificial intelligence is becoming increasingly relevant across SBS drug development and commercialization. AI-enabled literature mining, biomarker discovery, digital phenotyping, and trial feasibility modeling can help identify high-risk subgroups, optimize inclusion criteria, and accelerate recruitment in a rare disease where patient numbers are limited and care is concentrated in specialist centers.

In clinical and commercial settings, AI can support parenteral nutrition optimization, adverse event prediction, electronic health record screening, remote monitoring, and real-world evidence analytics. The highest-value use cases are those that improve patient monitoring while preserving clinician oversight, data privacy, interoperability, and regulatory-grade validation.

Key Regional Insights Across Global SBS Care

North America remains a leading SBS treatment region due to established home parenteral nutrition infrastructure, orphan-drug pathways, specialty pharmacy networks, payer experience with rare-disease therapies, and a high concentration of intestinal rehabilitation centers. Europe benefits from cross-border clinical expertise, national intestinal failure services, and EMA-recognized SBS therapies, although reimbursement timing, health technology assessment outcomes, and access to home parenteral nutrition vary by country.

Asia-Pacific is gaining relevance as Japan, China, Australia, South Korea, and India expand advanced gastroenterology, pediatric surgery, clinical nutrition, and tertiary hospital capabilities. Latin America shows growing need for SBS care in Mexico, Brazil, and other urban referral settings, but access is shaped by public-private reimbursement gaps and specialized nutrition support capacity. The Middle East, particularly Gulf health systems, is investing in specialty care and hospital infrastructure, while Africa faces a larger access barrier due to limited intestinal failure centers, uneven parenteral nutrition availability, infection-control challenges, and constrained reimbursement for orphan therapies.

Key Group Insights for SBS Market Access

Within the European Union, centralized regulatory pathways and national health technology assessments influence the adoption of GLP-2 analogs and home parenteral nutrition services, making country-level evidence packages essential for access. G7 markets typically offer stronger rare-disease infrastructure, specialist referral pathways, home-care services, and pharmacovigilance systems that support premium SBS therapies when they demonstrate clinically meaningful reductions in parenteral support.

ASEAN and BRICS countries represent long-term opportunities as tertiary hospitals expand gastrointestinal surgery, pediatric care, and clinical nutrition programs, although access remains uneven between major urban centers and broader public health systems. GCC markets are investing in advanced specialty care, international clinical standards, and hospital-based nutrition support, while NATO countries broadly benefit from resilient medical supply chains, established hospital procurement systems, and emergency preparedness frameworks relevant to parenteral nutrition, infusion supplies, and SBS therapy continuity.

Key Country Insights for SBS Market Prioritization

The United States leads SBS commercialization through orphan-drug incentives, specialist intestinal failure centers, home infusion networks, and specialty pharmacy distribution. Canada emphasizes evidence-based reimbursement and provincial access pathways, while Mexico and Brazil are building access through tertiary hospitals, gastroenterology referral centers, and private-sector specialty care. The United Kingdom, Germany, France, Italy, and Spain have strong gastroenterology and clinical nutrition expertise, but differ in reimbursement speed, regional budget controls, home parenteral nutrition organization, and health technology assessment requirements.

Russia’s access environment is influenced by localized procurement and specialty-care concentration in major cities. China and India offer significant unmet clinical need but uneven access to home parenteral nutrition, rare-disease reimbursement, and specialized intestinal rehabilitation services outside leading tertiary hospitals. Japan, Australia, and South Korea provide mature specialist networks, high-quality clinical governance, and established pathways for high-evidence therapies that reduce parenteral support burden and improve long-term SBS management.

Actionable Recommendations for SBS Industry Leaders

Industry leaders should prioritize evidence packages that connect SBS therapies to reduced parenteral nutrition volume, fewer infusion days, improved fluid balance, lower catheter complication risk, reduced hospitalization burden, and quality-of-life improvement. Outcomes should be measured through registries, long-term extension studies, patient-reported outcomes, and real-world evidence from intestinal failure centers.

Stakeholders should also build integrated access strategies covering specialist education, nutrition-team partnerships, home-care coordination, pediatric transition support, adherence services, and payer-ready health economic evidence. In rare SBS populations, durable leadership will depend on trust, safety transparency, evidence continuity, and practical support across diagnosis, treatment initiation, long-term monitoring, and home-based care.

Research Methodology for SBS Market Analysis

This executive summary is based on a structured review of publicly available clinical, regulatory, and healthcare delivery evidence related to short bowel syndrome, intestinal failure, parenteral nutrition, GLP-2 analog therapy, pediatric and adult care pathways, and regional access dynamics. Sources considered include regulatory approvals, clinical guidelines, peer-reviewed literature, health technology assessment principles, and rare-disease care infrastructure indicators.

Insights were synthesized using a triangulated approach that compares therapeutic standards, reimbursement conditions, regional healthcare capacity, clinical endpoint relevance, and stakeholder needs. The analysis avoids unverified market sizing, market share, and forecasting claims, and emphasizes evidence-backed drivers that shape clinical adoption, access, and commercialization strategy.

Conclusion: Strategic Outlook for Short Bowel Syndrome

Short bowel syndrome is evolving from a replacement-care condition into a targeted intestinal rehabilitation market. The clinical goal is no longer limited to survival on parenteral nutrition; it increasingly includes intestinal adaptation, fewer complications, improved independence, better hydration, and sustainable long-term outcomes.

For pharmaceutical innovators, the most attractive opportunities are therapies and support models that reduce parenteral dependence, demonstrate durable benefit, and integrate seamlessly into specialist SBS care. Evidence quality, access planning, home-care coordination, and patient-centered implementation will define competitive advantage in this rare and highly specialized treatment landscape.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Short Bowel Syndrome Market, by Treatment Type

7.1. Introduction
7.2. Nutritional Support
7.2.1. Parenteral Nutrition
7.2.2. Enteral Nutrition
7.3. Pharmacological Treatment
7.3.1. GLP-2 Analogues
7.3.2. Growth Hormone Therapy
7.3.3. Glutamine Therapy
7.3.4. Antibiotics
7.4. Surgical Treatment
7.4.1. Intestinal Lengthening Procedures
7.4.2. Intestinal Transplantation

8. Short Bowel Syndrome Market, by Route Of Administration

8.1. Introduction
8.2. Parenteral
8.2.1. Intravenous
8.2.2. Subcutaneous
8.3. Oral

9. Short Bowel Syndrome Market, by Patient Age

9.1. Introduction
9.2. Adult
9.3. Geriatric
9.4. Pediatric

10. Short Bowel Syndrome Market, by Etiology

10.1. Introduction
10.2. Trauma
10.3. Crohn’s Disease
10.4. Mesenteric Ischemia
10.5. Radiation Enteritis
10.6. Tumor Resection

11. Short Bowel Syndrome Market, by End Use

11.1. Introduction
11.2. Home Care Facilities
11.3. Hospitals
11.4. Specialty Clinics
11.5. Ambulatory Surgical Centers
11.6. Research Institutes

12. Short Bowel Syndrome Market, by Region

12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa

13. Short Bowel Syndrome Market, by Group

13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO

14. Short Bowel Syndrome Market, by Country

14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Ardelyx, Inc.
16.2. Emmaus Life Sciences, Inc.
16.3. Hanmi Pharmaceutical Co., Ltd.
16.4. Ironwood Pharmaceuticals, Inc.
16.5. Merck & Co., Inc.
16.6. NorthSea Therapeutics B.V.
16.7. Nutrinia Ltd.
16.8. OxThera AB
16.9. Pfizer Inc.
16.10. PhaseBio Pharmaceuticals, Inc.
16.11. Sancilio & Company, Inc.
16.12. Takeda Pharmaceutical Company Limited
16.13. Theriva Biologics, Inc.
16.14. Zealand Pharma A/S

List of Figures

FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025 VS 2032 (%)
FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NUTRITIONAL SUPPORT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PARENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ENTERAL NUTRITION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL PHARMACOLOGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GLP-2 ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GLP-2 ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GLP-2 ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL GROWTH HORMONE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL GROWTH HORMONE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL GROWTH HORMONE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GLUTAMINE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL GLUTAMINE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL GLUTAMINE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SURGICAL TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL INTESTINAL LENGTHENING PROCEDURES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL INTESTINAL LENGTHENING PROCEDURES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTESTINAL LENGTHENING PROCEDURES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTESTINAL TRANSPLANTATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTESTINAL TRANSPLANTATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTESTINAL TRANSPLANTATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TRAUMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TRAUMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TRAUMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CROHN’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CROHN’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CROHN’S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL MESENTERIC ISCHEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MESENTERIC ISCHEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MESENTERIC ISCHEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RADIATION ENTERITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL RADIATION ENTERITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL RADIATION ENTERITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TUMOR RESECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL TUMOR RESECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL TUMOR RESECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOME CARE FACILITIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOME CARE FACILITIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOME CARE FACILITIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 123. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 125. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 126. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 127. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 128. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 130. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 131. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 132. EUROPE SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 143. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 145. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 146. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 147. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 148. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 149. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 150. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 151. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 152. AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 155. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 156. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 157. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 158. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 159. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 160. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 161. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 162. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 163. ASEAN SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 164. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 166. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 167. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 168. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 169. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 171. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 172. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 173. GCC SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 184. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 185. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 186. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 187. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 188. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 189. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 190. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 191. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 192. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 193. BRICS SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 194. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 196. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 197. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 198. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 199. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 201. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 202. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 203. G7 SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 204. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 206. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 207. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 208. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 209. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 211. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 212. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 213. NATO SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 214. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 215. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 216. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 217. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 218. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 219. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 220. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 221. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 222. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 223. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 225. CANADA SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 227. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 228. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 229. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 230. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 231. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 232. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 233. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 234. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 235. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 237. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 238. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 239. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 240. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 242. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 243. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 244. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 245. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 247. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 248. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 249. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 250. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 252. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 253. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 254. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 255. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 256. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 257. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 258. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 259. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 260. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 261. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 262. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 263. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 264. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 265. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 266. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 267. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 268. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 269. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 270. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 271. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 272. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 273. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 274. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 275. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 276. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 277. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 278. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 279. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 280. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 281. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 282. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 283. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 284. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 285. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 287. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 288. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 289. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 290. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 292. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 293. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 294. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 295. ITALY SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 296. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 297. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 298. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 299. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 300. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 301. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 302. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 303. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 304. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 305. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 306. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 307. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 308. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 309. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 310. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 311. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 312. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 313. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 314. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 315. CHINA SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 317. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 318. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 319. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 320. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 321. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 322. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 323. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 324. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 325. INDIA SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 326. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 327. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 328. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 329. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 330. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 331. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 332. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 333. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 334. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 335. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 337. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 338. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 339. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 340. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 341. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 342. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 343. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 344. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 345. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 347. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY NUTRITIONAL SUPPORT, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY SURGICAL TREATMENT, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PARENTERAL, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY PATIENT AGE, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY ETIOLOGY, 2017-2032 (USD MILLION)
TABLE 354. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY END USE, 2017-2032 (USD MILLION)
TABLE 355. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 356. SOUTH

Companies Mentioned

Ardelyx, Inc.
Emmaus Life Sciences, Inc.
Hanmi Pharmaceutical Co., Ltd.
Ironwood Pharmaceuticals, Inc.
Merck & Co., Inc.
NorthSea Therapeutics B.V.
Nutrinia Ltd.
OxThera AB
Pfizer Inc.
PhaseBio Pharmaceuticals, Inc.
Sancilio & Company, Inc.
Takeda Pharmaceutical Company Limited
Theriva Biologics, Inc.
Zealand Pharma A/S

Table Information

Report Attribute	Details
No. of Pages	196
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 1.32 Billion
Forecasted Market Value ( USD ) by 2032	$ 2.31 Billion
Compound Annual Growth Rate	9.5%
Regions Covered	Global
No. of Companies Mentioned	14

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3180EUR$3,545USD£2,719GBP €3534EUR$3,939USD£3,021GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4811EUR$5,363USD£4,113GBP €5346EUR$5,959USD£4,570GBP

Transformative Shifts in the SBS Treatment Landscape

Cumulative Impact of Artificial Intelligence on SBS Innovation

Key Regional Insights Across Global SBS Care

Key Group Insights for SBS Market Access

Key Country Insights for SBS Market Prioritization

Actionable Recommendations for SBS Industry Leaders

Research Methodology for SBS Market Analysis

Conclusion: Strategic Outlook for Short Bowel Syndrome

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Short Bowel Syndrome (SBS) - Global Strategic Business Report

Short Bowel Syndrome - Market Insight, Epidemiology, and Market Forecast - 2036

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

Short Bowel Syndrome Market Report 2026

Short Bowel Syndrome Drug Pipeline Analysis Report 2026